STRATA Skin Sciences reports record Q4 revenue of $10.6M; FY 2023 guidance $38M-$40M

STRATA Skin Sciences, Inc.

2023-Q1 EPS reported -$0.08 revenue$7,567,000

Q4 2022 revenue $10.6M (+17% YoY); full-year revenue $36.2M (+21% YoY).
Net loss narrowed to $0.2M in Q4 ($0.005/share) vs $0.8M loss in Q4 2021; full-year net loss $5.5M vs $2.7M.
Domestic installed base of 909 XTRAC devices; acquired TheraClearX acne device in Jan 2022.
FY 2023 revenue guidance of $38M-$40M; entered Mexican market with distribution agreement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

STRATA Skin Sciences, Inc. reported the fourth fiscal quarter and full year ended December 31, 2022 results: revenue $10.6 million, net income Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share, EPS loss of $0.005 per basic and diluted common share. Guidance raised.

Period: the fourth fiscal quarter and full year ended December 31, 2022
Revenue: $10.6 million
Net income: Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share
EPS: loss of $0.005 per basic and diluted common share
Guidance: raised
Result: reported results

Exact text from the filing

results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Highlights: ● Revenue in the fourth quarter of 2022 was a record $10.6 million, an increase of 17% over the fourth quarter of 2021 ○ Global recurring revenue was $6.5 million ○ Gross domestic recurring billings were $5.8 million ● Revenue for the full year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

STRATA Skin Sciences, Inc. reported the fiscal year ended December 31, 2022 results: revenue $36.2 million, net income Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share, EPS loss of $0.16 per basic and diluted common share. Guidance raised.

Period: the fiscal year ended December 31, 2022
Revenue: $36.2 million
Net income: Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share
EPS: loss of $0.16 per basic and diluted common share
Guidance: raised
Result: reported results

Exact text from the filing

Revenues for the full year 2022 were $36.2 million

View on SEC.gov

Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-015159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.